PRLDPrelude Therapeutics Incorporated
$3.88+169% 1Y
$3.88
$1.1952 weeks$6.62
PRLD in its own filings
PRLD's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
126
Events found in the filings · across 389 filings · the record starts in 2020
- Hard flags
- 1
Hard flags
- Most recent filing
- Sep 10, 2026
Most recent filing · Form 8-K
- Record starts
- Aug 19, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 11, 2026
- Delisting notice / listing-rule failurepast_3y
- 2025-03-28
- SEC comment-letter activity18 occurrences
- 2025-12-15
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 10, 2026Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader.Regulation FD disclosure · press release
- Aug 11, 2026Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- May 12, 2026Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- Apr 21, 2026On April 20, 2026, Prelude Therapeutics Incorporated (“Prelude”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Evercore Group L.L.C. as representatives (the “Representatives”) of the underwriters named therein, pursuant to which Prelude agreed to issue and sell …Material agreement entered · Form 8-K
- Apr 20, 2026The Company will present preclinical data from its lead development candidate, PRT 13722, at the AACR Annual Meeting 2026 on April 20, 2026. Based on preclinical data, we believe PRT 13722 is a highly differentiated, first-in-class, orally bioavailable, potent and highly selective KAT6A degrader.Regulation FD disclosure · Form 8-K
- Apr 15, 2026On April 15, 2026 Prelude Therapeutics Incorporated, (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Charles Q. Morris, M.D., age 61, as the Chief Medical Officer of the Company, effective on April 20, 2026 (the “Appointment Date”)Director or officer change · Form 8-K
- Mar 12, 2026As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2023, Prelude Therapeutics Incorporated (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC, as sales agent (“Jefferies”), relating …Other event · Form 8-K
- Mar 10, 2026Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026.Earnings release · press release
- Feb 3, 2026Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor.Regulation FD disclosure · press release
- Jan 9, 2026Exclusive option agreement with Incyte (announced November 2025) Option Agreement With Incyte Provides Significant Capital to Further Advance Our JAK2V617F and KAT6A Programs.Regulation FD disclosure · press release
- Nov 12, 2025Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…